ABL1 T315I Recombinant Human Active Protein Kinase
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 T315I Recombinant Human Active Protein Kinase is a recombinant ABL1 T315I protein that can be used to study ABL1 T315I-related functions[1].
Product Specifications
UNSPSC
12352211
Target
Bcr-Abl
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
[ABL1T315IRecombinantHumanActiveProteinKinase]
References & Citations
[1]Yusoff YM, et al. Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance. Malays J Pathol. 2024 Dec;46 (3) :431-439.
Shipping Conditions
Room temperature
Scientific Category
Enzyme
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400050-500 1x 500 µL
IgA Secretory Component (SC05), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040257-100 1x 100 µL
Cytokeratin, HMW (AE-3), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680806-100 1x 100 µL
TYRP1 (Tyrosinase Related Protein 1) (TA99), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details